Scholarlink

Background <p>Glucose-lowering glucagon-like peptide-1 receptor agonists (GLP1RAs) are widely used to treat type 2 diabetes (T2D) and obesity. However, their potential benefits in pulmonary diseases remain unclear. To address this, we used Mendelian randomization (MR) analysis to assess the causal effects of genetically proxied GLP1RAs on chronic obstructive pulmonary disease (COPD) and related conditions, including bronchitis and asthma.</p> Methods <p>We selected cis-expression quantitative trait loci (cis-eQTLs) as instrumental variables to genetically proxy GLP1RAs. Summary-level data were obtained from the eQTLGen and FinnGen consortia. MR analyses were used to identify the association between genetically proxied GLP1RAs and COPD, as well as COPD-related diseases. T2D, HbA1c levels, and BMI were used as positive controls.</p> Results <p>After Benjamini-Hochberg correction for multiple testing, MR analyses indicated that genetically predicted GLP1RAs were significantly associated with lower risks of COPD (OR [95% CI] = 0.838 [0.74–0.948], <i>P</i> = 0.013), early-onset COPD (&lt; 65 years) (OR [95% CI] = 0.751[0.622–0.906], <i>P</i> = 0.01), COPD-related respiratory insufficiency (OR [95% CI] = 0.720[0.55–0.944], <i>P</i> = 0.024), acute bronchitis (OR [95% CI] = 0.787 [0.693–0.893], <i>P</i> = 0.002), asthma (OR [95% CI] = 0.872 [0.782–0.973], <i>P</i> = 0.023), and other symptoms and signs involving the circulatory and respiratory systems (OR [95% CI] = 0.426 [0.217–0.834], <i>P</i> = 0.023). No significant association was observed for later-onset COPD (<b>≥</b> 65 years) (OR [95% CI] = 0.921 [0.783–1.082], <i>P</i> = 0.315) or chronic bronchitis risk (OR [95% CI] = 0.950 [0.889–1.016], <i>P</i> = 0.146).</p> Conclusions <p>Genetically predicted GLP1RAs are associated with a lower risk of early-onset COPD, COPD-related respiratory insufficiency, acute bronchitis, and asthma. These findings highlight potential benefits of GLP1RAs in T2D patients with coexisting pulmonary diseases and support the need for further investigation in COPD management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association of GLP1RAs with risk of chronic obstructive pulmonary disease: evidence from drug target Mendelian randomization

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月28日

查看全文
  • Sijia Lai,
  • Yaohui Feng,
  • Lu Li,
  • Jiayu Zhao,
  • Zhenyu Wang,
  • Yanli Wang

摘要

Background

Glucose-lowering glucagon-like peptide-1 receptor agonists (GLP1RAs) are widely used to treat type 2 diabetes (T2D) and obesity. However, their potential benefits in pulmonary diseases remain unclear. To address this, we used Mendelian randomization (MR) analysis to assess the causal effects of genetically proxied GLP1RAs on chronic obstructive pulmonary disease (COPD) and related conditions, including bronchitis and asthma.

Methods

We selected cis-expression quantitative trait loci (cis-eQTLs) as instrumental variables to genetically proxy GLP1RAs. Summary-level data were obtained from the eQTLGen and FinnGen consortia. MR analyses were used to identify the association between genetically proxied GLP1RAs and COPD, as well as COPD-related diseases. T2D, HbA1c levels, and BMI were used as positive controls.

Results

After Benjamini-Hochberg correction for multiple testing, MR analyses indicated that genetically predicted GLP1RAs were significantly associated with lower risks of COPD (OR [95% CI] = 0.838 [0.74–0.948], P = 0.013), early-onset COPD (< 65 years) (OR [95% CI] = 0.751[0.622–0.906], P = 0.01), COPD-related respiratory insufficiency (OR [95% CI] = 0.720[0.55–0.944], P = 0.024), acute bronchitis (OR [95% CI] = 0.787 [0.693–0.893], P = 0.002), asthma (OR [95% CI] = 0.872 [0.782–0.973], P = 0.023), and other symptoms and signs involving the circulatory and respiratory systems (OR [95% CI] = 0.426 [0.217–0.834], P = 0.023). No significant association was observed for later-onset COPD (≥ 65 years) (OR [95% CI] = 0.921 [0.783–1.082], P = 0.315) or chronic bronchitis risk (OR [95% CI] = 0.950 [0.889–1.016], P = 0.146).

Conclusions

Genetically predicted GLP1RAs are associated with a lower risk of early-onset COPD, COPD-related respiratory insufficiency, acute bronchitis, and asthma. These findings highlight potential benefits of GLP1RAs in T2D patients with coexisting pulmonary diseases and support the need for further investigation in COPD management.